Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets
Open Access
- 12 September 2011
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 208 (10), 2017-2031
- https://doi.org/10.1084/jem.20110750
Abstract
It is believed that megakaryocytes undergo a specialized form of apoptosis to shed platelets. Conversely, a range of pathophysiological insults, including chemotherapy, are thought to cause thrombocytopenia by inducing the apoptotic death of megakaryocytes and their progenitors. To resolve this paradox, we generated mice with hematopoietic- or megakaryocyte-specific deletions of the essential mediators of apoptosis, Bak and Bax. We found that platelet production was unperturbed. In stark contrast, deletion of the prosurvival protein Bcl-xL resulted in megakaryocyte apoptosis and a failure of platelet shedding. This could be rescued by deletion of Bak and Bax. We examined the effect on megakaryocytes of three agents that activate the intrinsic apoptosis pathway in other cell types: etoposide, staurosporine, and the BH3 mimetic ABT-737. All three triggered mitochondrial damage, caspase activation, and cell death. Deletion of Bak and Bax rendered megakaryocytes resistant to etoposide and ABT-737. In vivo, mice with a Bak−/− Bax−/− hematopoietic system were protected against thrombocytopenia induced by the chemotherapeutic agent carboplatin. Thus, megakaryocytes do not activate the intrinsic pathway to generate platelets; rather, the opposite is true: they must restrain it to survive and progress safely through proplatelet formation and platelet shedding.This publication has 88 references indexed in Scilit:
- BH3-only Activator Proteins Bid and Bim Are Dispensable for Bak/Bax-dependent Thrombocyte Apoptosis Induced by Bcl-xL DeficiencyPublished by Elsevier BV ,2011
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- Drugs targeting Bcl-2 family members as an emerging strategy in cancerExpert Reviews in Molecular Medicine, 2010
- zVAD-induced necroptosis in L929 cells depends on autocrine production of TNFα mediated by the PKC–MAPKs–AP-1 pathwayCell Death & Differentiation, 2010
- Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineageProceedings of the National Academy of Sciences of the United States of America, 2009
- Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009Cell Death & Differentiation, 2008
- ATR: an essential regulator of genome integrityNature Reviews Molecular Cell Biology, 2008
- No death without life: vital functions of apoptotic effectorsCell Death & Differentiation, 2008
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune diseaseProceedings of the National Academy of Sciences of the United States of America, 2005